Second Genome has announced a deal with Pfizer to conduct a large microbiome observational study to find out more about obesity and metabolic diseases.

 

The study is aimed at evaluating clinical factors and the microbiome in a cohort of about 900 individuals with various metabolic phenotypes in order to elucidate the interrelationship between the microbiome, obesity, and metabolic disorders.

 

press release from Second Genome

article in GenomeWeb Daily News [registration required]

 

— UPCOMING EVENTS —

 

5/12 5:00 pm – 6:30 pm in New Haven

BioScienceClubhouseCT presents ‘SystaMedic: A Novel Cause-Effect Analysis Platform for Predicting Probability of R&D Program Success’  … more

 

5/14 9:00 am – 4:00 pm in New Haven

Diabetes Symposium: “Innovative Approaches to Diabetes Research and Therapies”  … more